Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Sparano

Showing results (241-250 of 293) with videos related to

Pageof 30
Sort By:
Journal of the National Cancer Institute|May 4, 2013
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breastLawrence J Solin, Robert Gray, Frederick L Baehner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2008
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratorySunil S Badve, Frederick L Baehner, Robert P Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 TrialNathaniel S O'Connell, Fengmin Zhao, Ju-Whei Lee, et al.
Cancer|November 14, 2023
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 StudyLakshmi Rajdev, Chia-Ching Jackie Wang, Himanshu Joshi, et al.
JAMA Oncology|October 16, 2025
Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ: A Randomized Clinical TrialSeema A Khan, Justin Romanoff, Constantine Gatsonis, et al.
Blood|May 21, 2020
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)Juan C Ramos, Joseph A Sparano, Amy Chadburn, et al.
NPJ Breast Cancer|June 13, 2023
Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapyGina Kim, Burcu Karadal-Ferrena, Jiyue Qin, et al.
JCO Global Oncology|July 23, 2020
Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming BarriersLilie L Lin, David S Lakomy, Elizabeth Y Chiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2018
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102Noah Kornblum, Fengmin Zhao, Judith Manola, et al.
JAMA Network Open|July 3, 2025
Quality of Life Among Patients With Ductal Carcinoma In SituVictoria J Dunsmore, Bradley S Snyder, Ilana F Gareen, et al.
Pageof 30

Showing results (241-250 of 293) with videos related to

Sort By:
Pageof 30
Journal of the National Cancer Institute|May 4, 2013
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breastLawrence J Solin, Robert Gray, Frederick L Baehner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2008
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratorySunil S Badve, Frederick L Baehner, Robert P Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 TrialNathaniel S O'Connell, Fengmin Zhao, Ju-Whei Lee, et al.
Cancer|November 14, 2023
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 StudyLakshmi Rajdev, Chia-Ching Jackie Wang, Himanshu Joshi, et al.
JAMA Oncology|October 16, 2025
Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ: A Randomized Clinical TrialSeema A Khan, Justin Romanoff, Constantine Gatsonis, et al.
Blood|May 21, 2020
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)Juan C Ramos, Joseph A Sparano, Amy Chadburn, et al.
NPJ Breast Cancer|June 13, 2023
Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapyGina Kim, Burcu Karadal-Ferrena, Jiyue Qin, et al.
JCO Global Oncology|July 23, 2020
Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming BarriersLilie L Lin, David S Lakomy, Elizabeth Y Chiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2018
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102Noah Kornblum, Fengmin Zhao, Judith Manola, et al.
JAMA Network Open|July 3, 2025
Quality of Life Among Patients With Ductal Carcinoma In SituVictoria J Dunsmore, Bradley S Snyder, Ilana F Gareen, et al.
Pageof 30